CSBR CHAMPIONS ONCOLOGY INC revenue, earnings and financials

For the quarter ended July 31, 2026, CHAMPIONS ONCOLOGY INC reported revenue of $15.2M (up 8.8% from a year earlier), net income of −$426K and diluted EPS of n/a; over the last four quarters revenue was $60.7M and net income $38.8K; for the fiscal year ended April 2026 revenue was $59.4M, up 4.4% on the year before.

CSBR annual revenue and earnings

• Fiscal year ended Apr 2026: revenue $59.4M, gross profit n/a, operating income −$1.14M, net income −$1.18K (margin 0.0%), EPS −$0.08
• Fiscal year ended Apr 2025: revenue $56.9M, gross profit n/a, operating income $4.55M, net income $4.70K (margin 0.0%), EPS $0.33
• Fiscal year ended Apr 2024: revenue $50.2M, gross profit n/a, operating income −$7.36M, net income −$7.28K (margin 0.0%), EPS −$0.54
• Fiscal year ended Apr 2023: revenue $53.9M, gross profit n/a, operating income −$5.26M, net income −$5.34M (margin -9.9%), EPS −$0.39
• Fiscal year ended Apr 2022: revenue $49.1M, gross profit n/a, operating income $607K, net income $548K (margin 1.1%), EPS $0.04

CSBR quarterly revenue and earnings

• Quarter ended Jul 31, 2026: revenue $15.2M (up 8.8% year over year), net income −$426K, EPS n/a
• Quarter ended Apr 30, 2026 (from the annual report): revenue $13.8M (up 12.0% year over year), net income $476K, EPS −$0.05
• Quarter ended Jan 31, 2026: revenue $16.6M (down 2.8% year over year), net income −$279K, EPS −$0.02
• Quarter ended Oct 31, 2025: revenue $15.0M (up 11.5% year over year), net income $268K, EPS $0.02
• Quarter ended Jul 31, 2025: revenue $14.0M (down 0.5% year over year), net income −$466K, EPS −$0.03
• Quarter ended Apr 30, 2025 (from the annual report): revenue $12.4M (down 11.8% year over year), net income −$6.53M, EPS −$0.12
• Quarter ended Jan 31, 2025: revenue $17.0M (up 41.8% year over year), net income $4.50M, EPS $0.31
• Quarter ended Oct 31, 2024: revenue $13.5M (up 16.6% year over year), net income $728K, EPS $0.05
• Quarter ended Jul 31, 2024: revenue $14.1M (up 11.9% year over year), net income $1.31M, EPS $0.09
• Quarter ended Apr 30, 2024 (from the annual report): revenue $14.0M (up 7.1% year over year), net income $7.16M, EPS −$0.01
• Quarter ended Jan 31, 2024: revenue $12.0M (down 5.9% year over year), net income −$2.53M, EPS −$0.19
• Quarter ended Oct 31, 2023: revenue $11.6M (down 19.0% year over year), net income −$2.07M, EPS −$0.15
• Quarter ended Jul 31, 2023: revenue $12.6M (down 8.6% year over year), net income −$2.57M, EPS −$0.19
• Quarter ended Apr 30, 2023 (from the annual report): revenue $13.1M (up 1.5% year over year), net income −$2.56M, EPS −$0.19
• Quarter ended Jan 31, 2023: revenue $12.8M (down 3.2% year over year), net income −$2.44M, EPS −$0.18
• Quarter ended Oct 31, 2022: revenue $14.3M (up 21.2% year over year), net income −$16.0K, EPS $0.00
• Quarter ended Jul 31, 2022: revenue $13.7M (up 22.1% year over year), net income −$319K, EPS −$0.02
• Quarter ended Apr 30, 2022 (from the annual report): revenue $12.9M, net income −$344K, EPS −$0.02
• Quarter ended Jan 31, 2022: revenue $13.2M, net income $787K, EPS $0.05
• Quarter ended Oct 31, 2021: revenue $11.8M, net income $277K, EPS $0.02

CSBR cash flow, buybacks and dividends

• Fiscal year ended Apr 2026: operating cash flow −$4.47M, share buybacks n/a
• Fiscal year ended Apr 2025: operating cash flow $7.39M, share buybacks $0
• Fiscal year ended Apr 2024: operating cash flow −$6.14M, share buybacks $634K
• Fiscal year ended Apr 2023: operating cash flow $3.97M, share buybacks $74.0K
• Fiscal year ended Apr 2022: operating cash flow $6.50M, share buybacks $0

CSBR balance sheet

• Jul 31, 2026: cash $4.36M, total assets $33.3M, total liabilities $28.8M, shareholders' equity $3.89M
• Apr 30, 2026: cash $4.87M, total assets $27.0M, total liabilities $22.9M, shareholders' equity $3.94M
• Jan 31, 2026: cash $7.13M, total assets $28.4M, total liabilities $24.1M, shareholders' equity $4.28M
• Oct 31, 2025: cash $8.52M, total assets $30.2M, total liabilities $25.9M, shareholders' equity $4.17M
• Jul 31, 2025: cash $10.3M, total assets $30.5M, total liabilities $27.0M, shareholders' equity $3.51M
• Apr 30, 2025: cash $9.79M, total assets $32.3M, total liabilities $28.6M, shareholders' equity $3.77M
• Jan 31, 2025: cash $3.20M, total assets $30.6M, total liabilities $25.2M, shareholders' equity $5.47M
• Oct 31, 2024: cash $2.75M, total assets $25.2M, total liabilities $24.6M, shareholders' equity $681K

What is CSBR's revenue?

CHAMPIONS ONCOLOGY INC reported $60.7M of revenue over its last four quarters, through July 31, 2026.

Is CSBR profitable?

Yes. CHAMPIONS ONCOLOGY INC earned $38.8K over the last four quarters.

CSBR ownership and insider trades · All stocks